Infectious Disease
RSSArticles
-
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: The FDA Pulls Another COX-2 Inhibitor Off the Market
The FDA has asked Pfizer to withdraw valdecoxib (Bextra) from the market due to safety concerns. -
The WHI Results on Urinary Incontinence
Conjugated equine estrogen alone and CEE + MPA increased the risk of urinary incontinence among continent women and worsened the characteristics of urinary incontinence among symptomatic women after 1 year. -
High-Dose Vitamin E Increases All-Cause Mortality
A meta-analysis of 19 clinical trials found that vitamin E intake greater than the recommended 400 IU/day found a statistically significant relationship between increased dosage and all-cause mortality when compared to both controls and lower doses. -
Idiopathic Edema and Obstructive Sleep Apnea in Women
In women, obstructive sleep apnea appears to be associated with idiopathic edema, even after controlling for obesity. -
Does Periodontal Inflammation Produce CAD?
This study provides evidence of a direct relationship between periodontal microbiology and subclinical atherosclerosis. This relationship exists independent of C-reactive protein. -
Full April 2005 Issue in PDF
-
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: Preparing for the Possibility of a Bird Flu Pandemic
The possibility of a bird flu pandemic has health officials worldwide in a high state of alert. -
After Vioxx: The Issue of Safety in Prescribing COX-2 Inhibitors
After the voluntary withdrawal of Vioxx from the market in September 2004 following reports of increased cardiovascular events associated with the drug, there was a call from some quarters for a similar action for all selective COX-2 inhibitors (coxibs). This article reviews the current clinical knowledge regarding the coxibs and their cardiovascular effects. Recommendations for prescribing anti-inflammatory drugs in common clinical situations are provided.